• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用前列腺健康指数和多参数磁共振成像开发一种预测临床显著前列腺癌的新型列线图。

Development of a novel nomogram for predicting clinically significant prostate cancer with the prostate health index and multiparametric MRI.

作者信息

Mo Li-Cai, Zhang Xian-Jun, Zheng Hai-Hong, Huang Xiao-Peng, Zheng Lin, Zhou Zhi-Rui, Wang Jia-Jia

机构信息

Department of Urology, Taizhou Hospital of Zhejiang Province affiliated with Wenzhou Medical University, Linhai, Taizhou, Zhejiang, China.

Department of Pathology, Taizhou Hospital of Zhejiang Province affiliated with Wenzhou Medical University, Linhai, Taizhou, Zhejiang, China.

出版信息

Front Oncol. 2022 Nov 29;12:1068893. doi: 10.3389/fonc.2022.1068893. eCollection 2022.

DOI:10.3389/fonc.2022.1068893
PMID:36523980
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9745809/
Abstract

INTRODUCTION

On prostate biopsy, multiparametric magnetic resonance imaging (mpMRI) and the Prostate Health Index (PHI) have allowed prediction of clinically significant prostate cancer (csPCa).

METHODS

To predict the likelihood of csPCa, we created a nomogram based on a multivariate model that included PHI and mpMRI. We assessed 315 males who were scheduled for prostate biopsies.

RESULTS

We used the Prostate Imaging Reporting and Data System version 2 (PI-RADS V2) to assess mpMRI and optimize PHI testing prior to biopsy. Univariate analysis showed that csPCa may be identified by PHI with a cut-off value of 77.77, PHID with 2.36, and PI-RADS with 3 as the best threshold. Multivariable logistic models for predicting csPCa were developed using PI-RADS, free PSA (fPSA), PHI, and prostate volume. A multivariate model that included PI-RADS, fPSA, PHI, and prostate volume had the best accuracy (AUC: 0.882). Decision curve analysis (DCA), which was carried out to verify the nomogram's clinical applicability, showed an ideal advantage (13.35% higher than the model that include PI-RADS only).

DISCUSSION

In conclusion, the nomogram based on PHI and mpMRI is a valuable tool for predicting csPCa while avoiding unnecessary biopsy as much as possible.

摘要

引言

在前列腺活检中,多参数磁共振成像(mpMRI)和前列腺健康指数(PHI)有助于预测临床显著性前列腺癌(csPCa)。

方法

为了预测csPCa的可能性,我们基于包含PHI和mpMRI的多变量模型创建了一个列线图。我们评估了315名计划进行前列腺活检的男性。

结果

我们使用前列腺影像报告和数据系统第2版(PI-RADS V2)来评估mpMRI,并在活检前优化PHI检测。单变量分析表明,PHI以77.77为临界值、PHID以2.36为临界值、PI-RADS以3为最佳阈值时可识别csPCa。使用PI-RADS、游离前列腺特异抗原(fPSA)、PHI和前列腺体积建立了预测csPCa的多变量逻辑模型。包含PI-RADS、fPSA、PHI和前列腺体积的多变量模型具有最佳准确性(AUC:0.882)。为验证列线图的临床适用性而进行的决策曲线分析(DCA)显示出理想的优势(比仅包含PI-RADS的模型高13.35%)。

讨论

总之,基于PHI和mpMRI的列线图是预测csPCa的有价值工具,同时尽可能避免不必要的活检。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8d/9745809/63dccf0560e7/fonc-12-1068893-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8d/9745809/ff6cc8e5b677/fonc-12-1068893-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8d/9745809/66b8cf5ebcac/fonc-12-1068893-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8d/9745809/d15238f8306f/fonc-12-1068893-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8d/9745809/58cf37dfb8dd/fonc-12-1068893-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8d/9745809/63dccf0560e7/fonc-12-1068893-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8d/9745809/ff6cc8e5b677/fonc-12-1068893-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8d/9745809/66b8cf5ebcac/fonc-12-1068893-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8d/9745809/d15238f8306f/fonc-12-1068893-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8d/9745809/58cf37dfb8dd/fonc-12-1068893-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8d/9745809/63dccf0560e7/fonc-12-1068893-g005.jpg

相似文献

1
Development of a novel nomogram for predicting clinically significant prostate cancer with the prostate health index and multiparametric MRI.利用前列腺健康指数和多参数磁共振成像开发一种预测临床显著前列腺癌的新型列线图。
Front Oncol. 2022 Nov 29;12:1068893. doi: 10.3389/fonc.2022.1068893. eCollection 2022.
2
Prostate health index density aids the diagnosis of prostate cancer detected using magnetic resonance imaging targeted prostate biopsy in Taiwanese multicenter study.前列腺健康指数密度有助于诊断台湾多中心研究中使用磁共振成像靶向前列腺活检检测到的前列腺癌。
J Chin Med Assoc. 2024 Jul 1;87(7):678-685. doi: 10.1097/JCMA.0000000000001117. Epub 2024 Jun 3.
3
Based on PI-RADS v2.1 combining PHI and ADC values to guide prostate biopsy in patients with PSA 4-20 ng/mL.基于 PI-RADS v2.1,结合 PHI 和 ADC 值指导 PSA 为 4-20ng/mL 的患者进行前列腺活检。
Prostate. 2024 Mar;84(4):376-388. doi: 10.1002/pros.24658. Epub 2023 Dec 20.
4
Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.开发一种结合多参数磁共振成像和前列腺特异性抗原(PSA)相关参数的列线图,以提高不同区域临床显著性癌症的检测率。
Prostate. 2022 Apr;82(5):556-565. doi: 10.1002/pros.24302. Epub 2022 Jan 31.
5
A prospective study of the prostate health index density and multiparametric magnetic resonance imaging in diagnosing clinically significant prostate cancer.一项前列腺健康指数密度和多参数磁共振成像在诊断临床显著前列腺癌中的前瞻性研究。
Investig Clin Urol. 2023 Jul;64(4):363-372. doi: 10.4111/icu.20230060.
6
How to avoid prostate biopsy in men with Prostate Image-Reporting and Data System 3 lesion? Development and external validation of new biopsy indication using prostate health index density.如何避免对前列腺影像报告和数据系统3类病变的男性进行前列腺活检?利用前列腺健康指数密度制定新的活检指征并进行外部验证。
Prostate Int. 2023 Sep;11(3):167-172. doi: 10.1016/j.prnil.2023.07.001. Epub 2023 Jul 11.
7
Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.前列腺影像报告和数据系统(PI-RADS)评分与指数病变和多灶性、临床显著前列腺癌的相关性。
Eur Urol Oncol. 2018 May;1(1):29-36. doi: 10.1016/j.euo.2018.01.002. Epub 2018 May 15.
8
Integration of PSAd and multiparametric MRI to forecast biopsy outcomes in biopsy-naïve patients with PSA 4~20 ng/ml.在前列腺特异性抗原(PSA)为4至20 ng/ml的初诊患者中,整合前列腺特异性抗原密度(PSAd)和多参数磁共振成像(MRI)以预测活检结果。
Front Oncol. 2024 Jul 4;14:1413953. doi: 10.3389/fonc.2024.1413953. eCollection 2024.
9
A 4K score/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer.基于 4K 评分/MRI 的列线图预测前列腺癌、临床显著前列腺癌和不利前列腺癌。
Cancer Rep (Hoboken). 2021 Aug;4(4):e1357. doi: 10.1002/cnr2.1357. Epub 2021 Mar 4.
10
Prostate Health Index and Multiparametric MRI: Partners in Crime Fighting Overdiagnosis and Overtreatment in Prostate Cancer.前列腺健康指数与多参数磁共振成像:对抗前列腺癌过度诊断和过度治疗的“犯罪伙伴”
Cancers (Basel). 2021 Sep 21;13(18):4723. doi: 10.3390/cancers13184723.

引用本文的文献

1
Development and validation of biopsy free nomograms for predicting clinically significant prostate cancer in men with PI-RADS 4 and 5 lesions.用于预测PI-RADS 4和5类病变男性患者临床显著性前列腺癌的非活检列线图的开发与验证
Sci Rep. 2025 Jan 20;15(1):2506. doi: 10.1038/s41598-025-86607-6.
2
Advances in multiparametric magnetic resonance imaging combined with biomarkers for the diagnosis of high-grade prostate cancer.多参数磁共振成像结合生物标志物在高级别前列腺癌诊断中的进展。
Front Surg. 2024 Jul 16;11:1429831. doi: 10.3389/fsurg.2024.1429831. eCollection 2024.
3
Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer.

本文引用的文献

1
Modified Prostate Health Index Density Significantly Improves Clinically Significant Prostate Cancer (csPCa) Detection.改良前列腺健康指数密度显著提高临床显著性前列腺癌(csPCa)的检测率。
Front Oncol. 2022 Apr 7;12:864111. doi: 10.3389/fonc.2022.864111. eCollection 2022.
2
Prostate Health Index Density Outperforms Prostate Health Index in Clinically Significant Prostate Cancer Detection.前列腺健康指数密度在临床意义重大的前列腺癌检测方面优于前列腺健康指数。
Front Oncol. 2021 Nov 19;11:772182. doi: 10.3389/fonc.2021.772182. eCollection 2021.
3
Prostate Health Index and Multiparametric MRI: Partners in Crime Fighting Overdiagnosis and Overtreatment in Prostate Cancer.
评估基于血液和尿液的生物标志物用于检测具有临床意义的前列腺癌。
Prostate Cancer Prostatic Dis. 2025 Mar;28(1):45-55. doi: 10.1038/s41391-024-00840-0. Epub 2024 Jun 10.
4
Incorporating PHI in decision making: external validation of the Rotterdam risk calculators for detection of prostate cancer.将 PHI 纳入决策制定中:用于前列腺癌检测的鹿特丹风险计算器的外部验证。
World J Urol. 2024 Mar 13;42(1):141. doi: 10.1007/s00345-024-04833-5.
5
A nomogram based on peripheral lymphocyte for predicting 8-year survival in patients with prostate cancer: a single-center study using LASSO-cox regression.基于外周血淋巴细胞的列线图预测前列腺癌患者 8 年生存率:使用 LASSO-cox 回归的单中心研究。
BMC Cancer. 2024 Feb 23;24(1):254. doi: 10.1186/s12885-024-11929-z.
前列腺健康指数与多参数磁共振成像:对抗前列腺癌过度诊断和过度治疗的“犯罪伙伴”
Cancers (Basel). 2021 Sep 21;13(18):4723. doi: 10.3390/cancers13184723.
4
Comparison of PHI and PHI Density for Prostate Cancer Detection in a Large Retrospective Caucasian Cohort.在一个大型回顾性白种人队列中比较 PHI 和 PHI 密度用于前列腺癌检测的效果。
Urol Int. 2022;106(9):878-883. doi: 10.1159/000517891. Epub 2021 Aug 25.
5
The prostate health index (PHI) density: Are there advantages over PHI or over the prostate-specific antigen density?前列腺健康指数(PHI)密度:与 PHI 或前列腺特异性抗原密度相比,它有什么优势?
Clin Chim Acta. 2021 Sep;520:133-138. doi: 10.1016/j.cca.2021.06.006. Epub 2021 Jun 5.
6
The Prostate Health Index aids multi-parametric MRI in diagnosing significant prostate cancer.前列腺健康指数有助于多参数 MRI 诊断显著前列腺癌。
Sci Rep. 2021 Mar 5;11(1):1286. doi: 10.1038/s41598-020-78428-6.
7
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
8
Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission.2020 年及以后的前列腺癌早期检测:欧盟和欧盟委员会的事实和建议。
Eur Urol. 2021 Mar;79(3):327-329. doi: 10.1016/j.eururo.2020.12.010. Epub 2020 Dec 29.
9
Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.前列腺影像报告和数据系统第 2 版检测临床显著前列腺癌的阳性预测值:系统评价和荟萃分析。
Eur Urol Oncol. 2021 Oct;4(5):697-713. doi: 10.1016/j.euo.2020.12.004. Epub 2020 Dec 25.
10
The predictive value of the prostate health index vs. multiparametric magnetic resonance imaging for prostate cancer diagnosis in prostate biopsy.前列腺健康指数与多参数磁共振成像对前列腺穿刺活检中前列腺癌诊断的预测价值。
World J Urol. 2021 Jun;39(6):1889-1895. doi: 10.1007/s00345-020-03397-4. Epub 2020 Aug 6.